GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » ROC %

Antengene (HKSE:06996) ROC % : -96.85% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Antengene ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Antengene's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -96.85%.

As of today (2025-04-01), Antengene's WACC % is 17.62%. Antengene's ROC % is -84.79% (calculated using TTM income statement data). Antengene earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Antengene ROC % Historical Data

The historical data trend for Antengene's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene ROC % Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC %
Get a 7-Day Free Trial -657.47 -371.77 -356.65 -189.85 -81.57

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -433.41 -208.62 -182.16 -96.85 -75.96

Antengene ROC % Calculation

Antengene's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-723.612 * ( 1 - 0% )/( (315.65 + 446.648)/ 2 )
=-723.612/381.149
=-189.85 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2392.182 - 385.51 - ( 1992.145 - max(0, 426.358 - 2117.38+1992.145))
=315.65

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1770.376 - 174.236 - ( 1292.774 - max(0, 208.789 - 1358.281+1292.774))
=446.648

Antengene's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-414.712 * ( 1 - 0% )/( (446.648 + 409.757)/ 2 )
=-414.712/428.2025
=-96.85 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1770.376 - 174.236 - ( 1292.774 - max(0, 208.789 - 1358.281+1292.774))
=446.648

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1573.219 - 174.937 - ( 1102.152 - max(0, 209.263 - 1197.788+1102.152))
=409.757

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antengene  (HKSE:06996) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Antengene's WACC % is 17.62%. Antengene's ROC % is -84.79% (calculated using TTM income statement data). Antengene earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Antengene ROC % Related Terms

Thank you for viewing the detailed overview of Antengene's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Antengene Business Description

Traded in Other Exchanges
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
Executives
Mei Jay 2201 Interest of corporation controlled by you
Jay Mei 2023 Grat 2201 Interest of corporation controlled by you
Begonia Investment Ltd. 2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Fountainvest China Capital Partners Gp3 Ltd. 2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p. 2201 Interest of corporation controlled by you
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Jay Mei 2020 Grat 2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene Headlines

No Headlines